Mergers, acquisitions, and restructuring - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Mergers, acquisitions, and restructuring
A roundup of company moves and positioning from the pharmaceutical and biotechnology industries and contract service providers.

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 3, Issue 9

London (Aug. 9)— Hikma Pharmaceuticals, a multinational pharmaceuticals group, agreed to acquire the entire issued share capital of Alkan Pharma, an Egyptian pharmaceuticals company, for a cash consideration of $60.5 million. The acquisition is scheduled to be completed in the second half of 2007, subject to meeting certain regulatory requirements. The acquisition will be funded entirely by debt.

New York (Aug. 8)American Oriental Bioengineering, a manufacturer and distributor of plant-based pharmaceutical and nutraceutical products, signed a legally binding letter of intent to acquire Guangxi Boke Pharmaceutical, a privately owned plant-based healthcare company, in a transaction valued at approximately $40.0 million.

Bad Vilbel, Germany (Aug. 3)Stada acquired the Russian pharmaceuticals group Makiz through a contract on the purchase of 100% of the shares of Zao Makiz-Pharma, Zao Skopinpharm and Zao Biodyne Pharmaceuticals. The contract was concluded by Stada's Russian subsidiary Nizhpharm Oao, Nizhny Novgorod. The staggered purchase price, which partly depends on the results of fiscal year 2007, is expected to amount to a total of approximately EUR 125 million ($172 million) less net debt of the group at closing, but will be EUR 135 million ($186 million) at maximum.

Los Angles, CA (Aug. 1)Abraxis BioScience, a biopharmaceutical company, acquired from Watson Pharmaceuticals a sterile injectable manufacturing facility located in Phoenix, Arizona. This facility, which has the ability to manufacture lyophilized powders, suspension products, and aqueous and oil solutions, currently manufactures products for Watson and other third parties.

South San Francisco, CA (Aug. 2)Genentech announced that the waiting period under the Hart-Scott-Rodino Act has expired and it has completed the acquisition of Tanox, Inc. Tanox shareholders approved the merger agreement on January 15, 2007.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here